store at low temperature | store at -80°C
Monalizumab 是一种新型靶向自然杀伤细胞群 2A (NKG2A) 的免疫检查点抑制剂。Monalizumab 是一种人源化抗 NKG2A 的单克隆抗体,可促使 IFN-γ 产生,从而激活自然杀伤细胞功能。Monalizumab 具有抗肿瘤活性,可用于研究颈部鳞状细胞癌 (HNSCC)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 4,390 | 现货 | ||
5 mg | ¥ 9,450 | 现货 | ||
10 mg | ¥ 12,700 | 现货 | ||
25 mg | ¥ 18,900 | 现货 | ||
50 mg | ¥ 25,500 | 现货 | ||
100 mg | ¥ 34,300 | 现货 |
产品描述 | Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab is a humanized monoclonal antibody against NKG2A that induces IFN-γ production, thereby activating natural killer cell function. Monalizumab has antitumor activity and can be used to study neck squamous cell carcinoma (HNSCC). |
体外活性 | NK cells were incubated with monalizumab (1μg/mL) at 4°C for 30 minutes, followed by detection of total surface NKG2A using anti-human IgG4 (Fc)-PE. The results showed that monalizumab enhances the anti-tumor activity of human NK cells[1]. |
体内活性 | Mice were intravenously injected with 200 μg of monalizumab, with an interval of 3-4 days, followed by intraperitoneal injection of 200 μg of RMP1-14. The results showed that monalizumab and RMP1-14 have synergistic effects in preclinical mouse tumor models[1]. |
分子量 | N/A |
CAS No. | 1228763-95-8 |
store at low temperature | store at -80°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Monalizumab 1228763-95-8 Cell Cycle/Checkpoint Immunology/Inflammation IFNAR Chk Inhibitor inhibitor inhibit